As the likely dynamics for US biosimilar competition to Humira come into sharper focus, Coherus has promised that its mid-2023 market entry with its just-approved Yusimry version will be accompanied by a “compelling value proposition,” months after rival Amgen’s biosimilar is expected to launch and around the same time as multiple other rivals are expected to hit the market.
Fresh from obtaining US Food and Drug Administration approval for its Yusimry (adalimumab-aqvh) biosimilar rival to Humira, Coherus BioSciences has promised to come to market with a “compelling value proposition” when it launches from 1 July 2023 under the terms of a settlement with originator AbbVie.
Coherus’ promise for Yusimry – the firm’s second approved US biosimilar, after the successful Udenyca (pegfilgrastim-cbqv) rival to Neulasta –...
Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.
Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.
Arizona’s governor Katie Hobbs pointed to Trump’s One Big Beautiful Bill and other federal failures as she signed an executive order to increase access to medications in her state.
